Sanofi’s fexinidazole, the first all-oral therapy for the treatment of human African trypanosomiasis (HAT), or sleeping sickness, has secured a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), the manufacturer has said.
Ook interessant voor je
